compound 3i (666-15)

Catalog No.S8846 Batch:S884601

Print

Technical Data

Formula

C33H31Cl2N3O5
Molecular Weight 620.52 CAS No. 1433286-70-4
Solubility (25°C)* In vitro DMSO 100 mg/mL (161.15 mM)
Ethanol 3 mg/mL (4.83 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 5.000mg/ml (8.06mM)
5% DMSO 95% Corn oil

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 2.500mg/ml (4.03mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Compound 3i (666-15) is a potent and selective inhibitor of CREB-mediated gene transcription (IC50 = 0.081 ± 0.04 μM) and also potently inhibits cancer cell growth without harming normal cells.
Targets
CREB [1]
81 nM
In vitro

Compound 3i (666-15) could potently inhibit cancer cell growth. In MDA-MB-231 and MDA-MB-468 cells, the GI50 for this compound is 73 and 46 nM, respectively. In A549 and MCF-7 cells, it exhibits robust activity as well with GI50 of 0.47 and 0.31 μM. It inhibits CREB’s transcription activity in living cells independent of direct CREB or CBP binding interaction.
In vivo

In an in vivo MDA-MB-468 xenograft model, compound 3i (666-15) completely suppresses tumor growth without overt toxicity. Preliminary toxicity studies show that intraperitoneal (ip) injection of 10 mg/kg of it is well tolerated in mice.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    HEK 293T cells

  • Concentrations

    0.05, 0.1, 0.5 μM

  • Incubation Time

    --

  • Method

    After treatment of HEK 293T cells with different concentrations of compound 3i (666-15), forskolin was added, and the relative mRNA level of Nurr1/NR4A2 was determined by qRT-PCR analysis.
Animal Study:

[1]
  • Animal Models

    6- to 8-week old BALB/c nude mouse inoculated subcutaneously at the right flank with MDA-MB-468 cells

  • Dosages

    10 mg/kg

  • Administration

    IP

References

  • https://pubmed.ncbi.nlm.nih.gov/26023867/

Selleck's compound 3i (666-15) Has Been Cited by 24 Publications

MLK4 promotes glucose metabolism in lung adenocarcinoma through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is regulated by KLF5 [ Oncogenesis, July 5, 2023, 35] PubMed: 37407566
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States [ Cancer Research, January 18, 2023, 264-284] PubMed: 36409824
Aspartate signaling drives lung metastasis via alternative translation [ Nature, January 1, 2025, 244-250] PubMed: 39743589
The delta subunit of the GABAA receptor is necessary for the GPT2-promoted breast cancer metastasis [ Theranostics, February 21, 2023, 1355-1369] PubMed: 36923530
Transcriptional Repression of CCL2 by KCa3.1 K+ Channel Activation and LRRC8A Anion Channel Inhibition in THP-1-Differentiated M2 Macrophages [ International Journal of Molecular Sciences, August 6, 2025, 7624]
Renalase activates mitochondrial leak metabolism in response to cellular stress and to repair damage after injury [ bioRxiv, August 20, 2025, 2025.08.19.671117] PubMed: 40894758
Transcriptional Repression of CCL2 by KCa3.1 K+ Channel Activation and LRRC8A Anion Channel Inhibition in THP-1-Differentiated M2 Macrophages [ Int J Mol Sci, 2025, 26(15)7624] PubMed: 40806751
Renalase activates mitochondrial leak metabolism in response to cellular stress and to repair damage after injury [ bioRxiv, 2025, 2025.08.19.671117] PubMed: 40894758
Characterization of dipyridamole as a novel ferroptosis inhibitor and its therapeutic potential in acute respiratory distress syndrome management [ Theranostics, 2024, 14(18):6947-6968] PubMed: 39629132
Enforced activation of the CREB/KDM2B axis prevents alcohol-induced embryonic developmental delay [ Cell Rep, 2024, 43(12):115075] PubMed: 39661511

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.